Interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, has become an attractive therapeutic target because it is widely expressed in several haematological malignancies, including AML and B cell precursor acute lymphoblastic leukaemia (BCP-ALL). This evidence concerns the gene IL3RA and acute myeloid leukemia.